Long Ideas - Pfizer’s (NYSE:PFE) developmental drug tofacitinib, originally indicated for Rheumatoid Arthirits, showed positive trial results in treating ulcerative colitis and has been moved into a Phase … Continue Reading
Read NowLong Ideas - Idenix Pharmaceuticals (NASDAQ:IDIX) announced today that the FDA has placed its lead compound for hepatitis C, IDX-184, on partial clinical hold. According to IDIX, the … Continue Reading
Read NowLong Ideas - The Cooper Companies (NYSE:COO) became known as a “sleep at night” stock, with this leading contact lens provider beating estimates 8 quarters in a row. … Continue Reading
Read NowLong Ideas - With the bad news on failed Alzheimer’s candidate bapineuzumab out of the way, Elan Corporation, plc (NYSE:ELN) is positioning itself for a brighter future. The … Continue Reading
Read NowLong Ideas - Synergy Pharmaceuticals (NASDAQ:SGYP) announced today that its Phase IIb/III trial testing lead drug plecanatide for chronic constipation is fully enrolled. The trial met its 880 … Continue Reading
Read NowLong Ideas - This morning, PropThink featured an update on Ventrus Biosciences (NASDAQ: VTUS) post its second quarter results, noting that the company has enough cash to get … Continue Reading
Read NowLong Ideas - Ventrus Biosciences (NASDAQ:VTUS) released second quarter results last night, and notably, the company reported that it has $29 million in cash, enough to fund operations … Continue Reading
Read Now